Business Context and Reporting Period
Company: TNF Pharmaceuticals, Inc. (Ticker: TNFA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: TNF is a clinical-stage pharmaceutical company developing two therapeutic platforms: Isomyosamine (an oral TNF-α inhibitor for autoimmune diseases) and Supera-CBD (a synthetic analog of CBD). The company has no product revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,124,743) | $(9,800,041) |
| Net Loss Attributable to Common Stockholders | $(1,938,239) | $(11,001,908) |
| Operating Expenses | $2,471,834 | $2,784,623 |
| Cash and Cash Equivalents (End of Period) | $73,244 | $225,655 |
| Marketable Securities | $5,805,331 | $1,509,358 |
| Total Assets | $18,780,598 | $21,421,084 |
| Working Capital | $1,840,793 | $(1,512,851) |
| Accumulated Deficit | $(131,076,525) | $(112,978,975) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly from $9.8 million in Q1 2024 to $1.1 million in Q1 2025. This improvement is primarily driven by a $1.28 million gain on the change in fair value of derivative liabilities in Q1 2025, compared to a $7.1 million loss on warrant liabilities in Q1 2024.
- Operating Expenses: Total operating expenses decreased by approximately $313,000 year-over-year. This was due to a $433,000 reduction in stock-based compensation and lower personnel costs, partially offset by a $347,000 increase in Research and Development (R&D) expenses related to Phase 2B study costs.
- Liquidity Position: Cash on hand declined to $73,244 from $225,655. However, marketable securities increased to $5.8 million from $1.5 million due to net sales of securities ($8.4M proceeds vs. $5.9M purchases).
- Capital Structure: Significant conversions of Series F, F-1, and G Preferred Stock into Common Stock occurred during the quarter, increasing common shares outstanding from 3.36 million to 7.39 million.
Outlook, Risks, and Contingencies
- Going Concern: The company has substantial doubt about its ability to continue as a going concern for the next 12 months. Continued operations depend on obtaining additional capital financing through equity or debt offerings. If funding is not secured, the company may need to curtail operations.
- Nasdaq Compliance: On March 17, 2025, the company received notice from Nasdaq that it failed to meet the $1.00 minimum bid price requirement. The company has a 180-day compliance period (until September 15, 2025) to regain compliance.
- Preferred Stock Amendments: In April 2025 (subsequent to period end), the company amended Series F and F-1 Preferred Stock terms, extending maturity dates and modifying installment schedules. Additionally, a stock option grant on April 11, 2025, triggered a full ratchet anti-dilution adjustment, lowering conversion prices to $0.1832 per share.
- Litigation: The company is involved in ongoing litigation with Raymond F. Akers, Jr., regarding whistleblower retaliation claims. Management does not currently believe this will have a material impact on financial condition.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.8 million in marketable securities to fund operations given the $2.6 million quarterly operating cash burn.
- Dilution Risk: Assess the impact of the recent full ratchet anti-dilution adjustments (conversion price dropped to $0.1832) on existing common shareholders.
- Nasdaq Status: Monitor the company's ability to maintain a $1.00 closing bid price for 10 consecutive days within the compliance period to avoid delisting.
- Preferred Stock Obligations: Review the terms of Series F, F-1, and G Preferred Stock, including accrued dividends (10-15% annual rates) and redemption/installment requirements.
- R&D Progress: Confirm the status and funding requirements for the Isomyosamine Phase 2B study, which drove the increase in R&D expenses.